Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP521213.RAD-NZbtBRHMyR1QlRjjbEwQ9T6VI_b6FCLb8w_V1nBK0130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521213.RAD-NZbtBRHMyR1QlRjjbEwQ9T6VI_b6FCLb8w_V1nBK0130_provenance.
• NP464698.RAwNwKB_WqebmfYgg9x5zboFsp3Z74PAdb--QTXfjsFj4130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP464698.RAwNwKB_WqebmfYgg9x5zboFsp3Z74PAdb--QTXfjsFj4130_provenance.
• NP405096.RAIoKbZ0RNvbeZMuNXTnHS9rA6YW1qlQUDwLamlpjW77g130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP405096.RAIoKbZ0RNvbeZMuNXTnHS9rA6YW1qlQUDwLamlpjW77g130_provenance.
• NP187941.RAGA8AMGwYDxpC5YAMNiHUtMPaJXPOektDY3nLYfwpFsY130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP187941.RAGA8AMGwYDxpC5YAMNiHUtMPaJXPOektDY3nLYfwpFsY130_provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP278864.RAcAM8lK40kzImkL8MOi-5S-U2JGQZ5V9S2aJ_n4L78ps130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278864.RAcAM8lK40kzImkL8MOi-5S-U2JGQZ5V9S2aJ_n4L78ps130_provenance.
• NP278867.RAZ9EWRiReh1xseCBT20jFnqS-QTAecr5ZkN47r-oGTgg130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278867.RAZ9EWRiReh1xseCBT20jFnqS-QTAecr5ZkN47r-oGTgg130_provenance.
• NP677968.RArvYawtCbcqZZFoIYu9oj2hdecDLI12JeiXsOSrq-Kgk130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP677968.RArvYawtCbcqZZFoIYu9oj2hdecDLI12JeiXsOSrq-Kgk130_provenance.
• NP278871.RAgCxeeAjAV_7i_iwH3TSUqCkpgKLrPRAaLLsFoPJ1i4U130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278871.RAgCxeeAjAV_7i_iwH3TSUqCkpgKLrPRAaLLsFoPJ1i4U130_provenance.
• NP301410.RA993hb01uzXxcZ8HFILt0RgBefgjR0CU1rM7L9PEYtpk130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP301410.RA993hb01uzXxcZ8HFILt0RgBefgjR0CU1rM7L9PEYtpk130_provenance.
• NP680817.RANK7lNRHXQqjKMOKeJCAH7sj3WcxAqeqVgttNe4kHHSw130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680817.RANK7lNRHXQqjKMOKeJCAH7sj3WcxAqeqVgttNe4kHHSw130_provenance.
• NP677954.RA_6czs3Jm7n2vHAYK2DF89OLTNYqtcrkVw1Gz6EVlBuk130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP677954.RA_6czs3Jm7n2vHAYK2DF89OLTNYqtcrkVw1Gz6EVlBuk130_provenance.
• NP278863.RAJXzMx7rS43mGaKkrEGxDkyln7s555gSyAyfn5xXRrkU130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278863.RAJXzMx7rS43mGaKkrEGxDkyln7s555gSyAyfn5xXRrkU130_provenance.
• NP278868.RAPPXo-ByfL7fp9lmij-btJNvHR4PTaCIzQpS03R2VQKw130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278868.RAPPXo-ByfL7fp9lmij-btJNvHR4PTaCIzQpS03R2VQKw130_provenance.
• NP278872.RANiSOQhck7K5vFfcFYJFmQnd7v4Yd_sn5y69W_P89udk130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278872.RANiSOQhck7K5vFfcFYJFmQnd7v4Yd_sn5y69W_P89udk130_provenance.
• NP680813.RA0RM4cyks0e7WeQLpn5OKrw3Ndm5WnmbXhED3QsRogBQ130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP680813.RA0RM4cyks0e7WeQLpn5OKrw3Ndm5WnmbXhED3QsRogBQ130_provenance.
• NP278869.RA9nXajUNnl261m49q37_5IxBACl8-zMT4-OfC7Bin_0k130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278869.RA9nXajUNnl261m49q37_5IxBACl8-zMT4-OfC7Bin_0k130_provenance.
• NP278870.RA138KxnbTf7NCfjNpwni_fZh7dUm53VsMNwkusaUkmdM130_assertion description "[In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278870.RA138KxnbTf7NCfjNpwni_fZh7dUm53VsMNwkusaUkmdM130_provenance.